Importance No therapy directed against diabetes has been shown to unequivocally reduce
the excess risk of cardiovascular complications. Aleglitazar is a dual agonist of peroxisome
proliferator–activated receptors with insulin-sensitizing and glucose-lowering actions and
favorable effects on lipid profiles. Objective To determine whether the addition of aleglitazar
to standard medical therapy reduces cardiovascular morbidity and mortality among patients
with type 2 diabetes mellitus and a recent acute coronary syndrome (ACS). Design, Setting …